Myositis Specific 11 Antibody Panel

PL-7, PL-12, Mi-2, Ku, EJ, OJ, SRP, U3-RNP, U2-RNP, Jo-1, TIF-1gamma, MDA-5 (CADM-140), NXP-2 (P140), PM/Scl-100, SS-A 52kD, U1-RNP, Myositis Panel 3, Myomarker 3, Myositis Assessor, MyoMarker 3 Profile, Myositis Autoantibodies, nti-p155/140,Nuclear matrix protein,Anti-p140 antibody, JDM, Juvenile dermatomyositis, NuRD Complex, TIF 1-gamma antibody, Necrotizing myopathy, Polymyositis, Dermatomyositis, Anti-synthetase syndrome, Paraneoplastic myositis, Autoimmune myopathy, Myopathy, Transfer RNA synthetase antibody, SRP Signal recognition protein AB, CADM140, Amyopathic dermatomyositis

NOTE: Test includes:
Jo-1 Ab, Pl-7 Ab, Pl-12 Ab, EJ Ab, OJ Ab, SRP Ab, Mi-2 Alpha Ab, Mi-2 Beta Ab, MDA5 Ab, TIF1 Gamma Ab, NXP-2 Ab

Test Codes

EPIC: LAB1232021, Beaker: MYOSITISAB, Quest: 94777

Department

Send Outs

Specimen Collection Criteria

Collect: One Gold-top SST tube. 

Also acceptable: One plain Red-top tube.

Physician Office/Draw Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within four hours of collection. Transfer serum to plastic transport tube and maintain at room temperature (20-26°C or 68-78.8°F) prior to transport.

Preparation for Courier Transport

Transport:  0.5 mL serum, at room temperature (20-26°C or 68-78.8°F). (Minimum: 0.3 mL)

Rejection Criteria

Specimens not collected and processed as indicated.

In-Lab Processing

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within four hours of collection. Transfer serum to plastic transport tube and maintain at room temperature (20-26°C or 68-78.8°F).
 
Transport:  0.5 mL serum, room temperature (20-26°C or 68-78.8°F). (Minimum: 0.3 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 7 days
Refrigerated (2-8°C or 36-46°F): 14 days
Frozen (-20°C/-4°F or below): 28 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Quest Diagnostics, Wood Dale, IL.

Performed

Varies.
Results available in 3-5 days.

Reference Range

Jo-1 Ab	<11 SI
PL-7 Ab	<11 SI
PL-12 Ab	<11 SI
EJ Ab	<11 SI
OJ Ab	<11 SI
SRP Ab	<11 SI
Mi-2 Alpha Ab	<11 SI
Mi-2 Beta Ab	<11 SI
MDA5 Ab	<11 SI
TIF1 Gamma Ab	<11 SI
NXP-2 Ab	<11 SI

Test Methodology

Line Blot

Clinical Utility

Myositis Specific 11 Antibody Panel - Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodeling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.

CPT Codes

86235 x7, 84128 x6.

Contacts

Last Updated

12/19/2025